pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Clinical outcomes after PS matching between clopidogrel vs cilostazol and clopidogrel vs sarpogrelate

Clopidogrel vs. Cilostazol (5:1)Clopidogrel vs. Sarpogrelate (1:1)

Clopidogrel (n=395)Cilostazol (n=79)p-valueClopidogrel (n=64)Sarpogrelate (n=64)p-value
MACCE54(13.67)12(15.19)0.7226(9.38)1.000
Death9(2.28)1(1.27)1.0001(1.56)1(1.56)1.000
CV death3(0.76)0(0)1.0001(1.56)0(0)1.000
Non-CV death6(1.52)1(1.27)1.0000(0.00)1(1.06)1.000
Overall MI28(7.09)7(8.86)0.5822(3.13)2(3.13)1.000
MI (new onset)23(5.82)6(7.59)0.6051(1.56)0(0.00)1.000
MI (recurrent)5(1.27)1(1.27)1.0001(1.56)2(3.13)1.000
Stroke19(4.81)4(5.06)1.0005(7.81)3(4.69)0.718
Stroke, ischemic13(3.29)3(3.80)0.7383(4.69)3(4.69)1.000
PVD1 (0.25)1(1.27)0.3060(0)0(0)-

MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; PVD, peripheral vascular disease

Korean J Clin Pharm 2019;29:254-66 https://doi.org/10.24304/kjcp.2019.29.4.254
© 2019 Korean J Clin Pharm